Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum

International Journal of Immunopathology and Pharmacology

Volumn 27, Issue 1, 2014, Pages 143-146

  Santino, I ^a   Alari, A ^a   Bono, S ^b   Teti, E ^c   Marangi, M ^c   Bernardini, A ^a   Magrini, L ^a   Di Somma, S ^a   Teggi, A ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Genoma Molecular Genetics Laboratory   (Italy)

^c Department of Medical Sciences ^*  (Italy)

Author keywords

Clostridium difficile; Fungemia; Probiotics; Saccharomyces cerevisiae

Indexed keywords

AGAR; AMPHOTERICIN B; C REACTIVE PROTEIN; CASPOFUNGIN; CEFTRIAXONE; FLUCONAZOLE; HEMOGLOBIN; ITRACONAZOLE; PROBIOTIC AGENT; PROCALCITONIN; VANCOMYCIN; VORICONAZOLE; ANTIFUNGAL AGENT; ECHINOCANDIN;

ABDOMINAL RADIOGRAPHY; AGED; ANTIBIOTIC THERAPY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOOD CULTURE; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; EMERGENCY WARD; EPSILOMETER TEST; FECES ANALYSIS; FECES CULTURE; FEVER; FUNGEMIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOFLUORESCENCE TEST; INFECTION; MALE; PANCOLITIS; PRIORITY JOURNAL; RISK FACTOR; SACCHAROMYCES BOULARDII; SACCHAROMYCES CEREVISIAE; VERY ELDERLY; ENZYME LINKED FLUORESCENT IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; INDWELLING CATHETER; LEUKOCYTE COUNT; NONHUMAN; BLOOD; CHEMICALLY INDUCED DISORDER; CLOSTRIDIUM DIFFICILE; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; LETTER; MICROBIOLOGY; PSEUDOMEMBRANOUS COLITIS; TREATMENT OUTCOME;

AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CATHETERS, INDWELLING; CLOSTRIDIUM DIFFICILE; ECHINOCANDINS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FUNGEMIA; HUMANS; MALE; PROBIOTICS; SACCHAROMYCES CEREVISIAE; TREATMENT OUTCOME;

EID: 84900563292     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201402700120     Document Type: Article

References (26)

1. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infection due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 1:48-66. (Pubitemid 38379951)
2. Santino I, Bono S, Borruso L, Bove M, Cialdi E, Martinelli D, Alari A. Kodamaea ohmeri isolate from two immunocompromised patients: first report in Italy. Mycoses 2013; 56:179-81.
3. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998; 26:1027-36.
4. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-7. (Pubitemid 47101025)
5. Miceli MH, Diaz JA, Samuel AL. Emerging opportunistic yeast infections. Lancet Infect Dis 2011; 11:142-51.
6. Boirivant M, Strober W. The mechanism of action of probiotics. Curr Opin Gastroenterol 2007; 23:679-92. (Pubitemid 47508800)
7. Kelesidis T, Pothoulakis C. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Ther Adv Gastroenterol 2012; 5:112-25.
8. Lherm T, Monet C, Nougiere B, Soulier M, Larbi D, Le Gall C, Caen D, Malbrunot C. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002; 28:797-801. (Pubitemid 34639496)
9. Piarroux R, Millon L, Bardonnet K, Vagner O, Koenig H. Are live Saccharomyces yeasts harmful to patients? Lancet 1999; 353:1851-2. (Pubitemid 29251022)
10. Taylor GD, Buchanan-Chell M, Kirkland T, McKenzie M, Wiens R. Trends and sources of nosocomial fungaemia. Mycoses 1994; 37:187-90.
11. Aucott JN, Fayan J, Grossnicklas H, Morrissey A, Lederman MM, Salata RA. Invasive infection with Saccharomyces cerevisiae: report of three cases and review. Rev Infect Dis 1990; 12:406-11. (Pubitemid 20174593)
12. Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med 1998; 105:71-2. (Pubitemid 28346111)
13. Niault M, Thomas F, Prost J, Hojjat Ansari F, Kalfon P. Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii. Clin Infect Dis 1999; 28:930. (Pubitemid 29169454)
14. Perapoch J, Planes AM, Querol A, López V, Martínez-Bendayan I, Tormo R, Fernandez F, Peguero G, Salcedo S. Fungemia with Saccharomyces cerevisiae in two newborns, only one of whom had been treated with ultra-levura. Eur J Clin Microbiol Infect Dis 2000; 19:468-70. (Pubitemid 30458658)
15. Riquelme AJ, Calvo MA, Guzman AM, Depix MS, Garcia P, Perez C, Arrese M, Labarca JA. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol 2003; 36:41-3. (Pubitemid 36005347)
16. Smith D, Metzgar D, Wills C, Fierer J. Fatal Saccharomyces cerevisiae aortic graft infection. J Clin Microbiol 2002; 40:2691-2. (Pubitemid 34747394)
17. Herbrecht R, Nivoix Y. Saccharomyces cerevisiae Fungemia: an adverse effect of Saccharomyces boulardii probiotic administration. Clin Infect Dis 2005; 40:1635-7. (Pubitemid 40720814)
18. Stein PD, Folkens AT, Hruska KA. Saccharomyces fungemia. Chest 1970; 58:173-5.
19. Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005; 40:1625-34. (Pubitemid 40720813)
20. Graf C, Gavazzi G. Saccharomyces cerevisiae fungemia in an immunocompromised patient not treated with Saccharomyces boulardii preparation. J Infect 2007; 54:310-1. (Pubitemid 46238162)
21. Piechno S, Seguin P, Gangneux JP. Saccharomyces boulardii fungal sepsis: beware of the yeast. Can J Anaesth 2007; 54:245-6
22. Stefanatou E, Kompoti M, Paridou A, et al. Probiotics sepsis due to Saccharomyces fungaemia in a critically ill burn patient. Mycoses 2011; 54:643-6.
23. Kliemann DA, Antonello VS, Severo LC, Pasqualotto AC. Saccharomyces cerevisiae oesophagitis in a patient with oesophageal carcinoma. J Infect Dev Ctries 2011; 5:493-5.
24. Thygesen JB, Glerup H, Tarp B. Saccharomyces boulardii fungemia caused by treatment with a probiotics. BMJ Case Rep 2012; 27:1-2.
25. Chioukh FZ, Ben Hmida H, Ben Ameur K, Toumi A, Monastiri K. Saccharomyces cerevisiae fungemia in a premature neonate treated receiving probiotics. Med Mal Infect 2013; 43:359-60.
26. Lolis N, Veldekis D, Moraitou H, et al. Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin. Crit Care 2008; 12:414.